Skip to content

Updates

What's New in AusDI – May 2025

Browse the latest AusDI drug updates and medicines information – created and curated by trusted Australian editorial pharmacists, monthly.

Drug Monographs

Content Updates to Monographs

As part of our rigorous editorial updating process, the AusDI editorial team monitors safety information issued by the Australian Therapeutic Goods Administration (TGA), the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), the New Zealand Medicines and Medical Devices Safety Authority (Medsafe), and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). FDA-approved indications and dosing information in adults and children are also reviewed by our editorial team and included in selected monographs.

The Acetazolamide (Systemic) monograph has been updated with information on non-cardiogenic pulmonary oedema based on changes to product information. Cases of non-cardiogenic pulmonary oedema have been reported with acetazolamide (including severe cases occurring after a single dose) and have typically occurred within minutes to hours after administration of acetazolamide. If non-cardiogenic pulmonary oedema is suspected, it is recommended that acetazolamide be withdrawn and supportive treatment given. It is recommended that acetazolamide not be administered to patients who have previously experienced non-cardiogenic pulmonary oedema with acetazolamide.

Past Content Updates

April 2025

The Isotretinoin (Systemic) monograph has been updated with information on sexual disorders based on changes to product information. Anhedonia, decreased libido, erectile dysfunction, gynaecomastia, and vulvovaginal dryness have been reported with isotretinoin. It is recommended that patients be asked about signs or symptoms of sexual dysfunction before starting isotretinoin treatment, and monitored during treatment for the development of new sexual disorders. Discontinuation of isotretinoin treatment may not alleviate symptoms and further specialist evaluation may be required.

March 2025

The Influenza Virus Vaccine (Systemic) monograph has been updated with information for the Australian 2025 influenza season. The composition of the 2025 vaccine differs from the 2024 southern hemisphere and 2024/2025 northern hemisphere recommendations with the inclusion of one new strain for the influenza A(H3N2) subtype virus component.

February 2025

The Bupropion (Systemic) monograph has been updated with information on Brugada syndrome based on changes to product information. The use of bupropion may unmask Brugada syndrome, a rare genetic disease of the cardiac sodium channel characterised by electrocardiogram (ECG) changes, which may result in cardiac arrest and/or sudden death. Caution is recommended in patients with Brugada syndrome or risk factors such as a family history of cardiac arrest or sudden death.

New Product Summary

Abilify Asimtufii

Amvuttra

Apohealth Allergy and Hayfever Relief

Apohealth Melatonin Sleep Aid

ARX-Ezetimibe

Bylvay

Chemists' Own Allermist

Chemists' Own Favic for Cold Sores

Chemists' Own Melatonin Sleep Aid

Ephedrine-Hameln

FluMist Quadrivalent

Ganirelix Lupin

Iqirvo

Ixifi

Medsurge Magnesium Sulfate Heptahydrate

Nebaloc

Oridopa

Paramyl Osteo

Prasugrel Lupin

Prazosin Hydrochloride USP [Novitium Pharma]

Rivaxib

Syfovre

Tenofovir/Emtricitabine APX

Vyloy

Vyvgart

New Product Information

Apohealth Allergy And Hayfever Relief Nasal Spray

Apohealth Melatonin Sleep Aid

Bylvay

Chemists' Own Allermist

Flumist Quadrivalent

Iqirvo

Ixifi

Syfovre

Vyloy

Product information with an update to safety includes Abrysvo, Ajovy, Aldurazyme, Allosig, Apo-Allopurinol, Apo-Azathioprine, Apo-Esomeprazole, Apo-Ezetimibe/Simvastatin, Apo-Isotretinoin, Apo-Rabeprazole, Apretude, Austrapen, Avonex, Azathioprine Sandoz, Bavencio, Brufen Plus, Brufen Tablets, Budenofalk Foam, Caldolor, Caprelsa, Ceftriaxone Viatris, Celebrex, Clarithro, Clopixol, Clozaril, Cosentyx, Cozaar, Darzalex, DBL Dexamethasone Sodium Phosphate, Depo-Medrol, Depo-Nisolone, Diprivan, Emgality, Entrip, Epkinly, Esomeprazole Viatris, Ezetrol, Fluconazole Sandoz Capsules, Fluorescite, Fonat, Gilenya, Halaven, Hemlibra, Humira, Inflectra, Kimmtrak, Leflunomide Sandoz, Lenvima, Levoxine, Lynparza Tablets, Menveo, Mersynofen, Nplate, Ocrevus, Olumiant, Oratane, Ovestin Tablets, Ozempic, Ozole, Paxlovid, Plegridy, Precedex, Precedex Ready to Use, Primoteston Depot, Primovist, Provive, Relfydess, Solu-Cortef, Solu-Medrol, Sunitinib Sandoz, Sunlenca, Tecentriq, Tecentriq SC, Tecvayli, Telfast Decongestant, Thioprine, Tolak 4% Once Daily, Tramadol Sandoz Injection, Tramadol Sandoz SR, Trikafta, Trileptal, Trodelvy, Twinrix Preservative Free, Zabep, Zeposia, and Zyloprim.

Product information with an update to indications includes Boostrix-IPV, Cresemba, Enhertu, Fasenra, Kisqali, Sandoz Lamotrigine, and Venclexta.

Try AusDI for FREE

To try one of Australia’s most efficient and comprehensive drug information databases, register for a 14-day FREE trial by filling in the form below.

We’ll be in touch with more information to help you get started soon.